

\_STIMULATED\_VS\_UNSTIMULATED\_10W\_DN, FLETCHER\_PBMC\_BCG\_10W\_INFANT\_PPD\_STIMULATED\_VS\_UNSTIMULATED\_10W\_DN

ZAK\_PBMC\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_AD5\_NAB\_TITERS\_GT\_200\_VS\_LTE\_200\_1DY\_DN, ZAK\_PBMC\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_AD5\_NAB\_TITERS\_GT\_200\_VS\_LTE\_200\_1DY\_DN  
GARCIA\_PINERES\_PBMC\_HPV\_16\_L1\_VLP\_AGE\_18\_25YO\_STIMULATED\_VS\_UNSTIMULATED\_0DY\_VACCINATION\_INDEPENDENT\_DN, GARCIA\_PINERES\_PBMC\_HPV\_16\_L1\_VLP\_AGE\_18\_25YO\_STIMULATED\_VS\_UNSTIMULATED\_0DY\_VACCINATION\_INDEPENDENT\_DN  
HOWARD\_NK\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_28DY\_DN, HOWARD\_NK\_CELL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_28DY\_DN  
LI\_PBMC\_MENACTRA\_AGE\_18\_45YO\_CORRELATED\_WITH\_ANTI\_POLYSACCHARIDE\_ANTIBODY\_3DY\_POSITIVE, LI\_PBMC\_MENACTRA\_AGE\_18\_45YO\_CORRELATED\_WITH\_ANTI\_POLYSACCHARIDE\_ANTIBODY\_3DY\_POSITIVE  
THAKAR\_PBMC\_INACTIVATED\_INFLUENZA\_AGE\_70PLS\_NONRESPONDER\_2DY\_DN, THAKAR\_PBMC\_INACTIVATED\_INFLUENZA\_AGE\_70PLS\_NONRESPONDER\_2DY\_DN  
LI\_PBMC\_MENACTRA\_AGE\_18\_45YO\_ANTI\_DT\_ANTIBODY\_CORRELATION\_PROFILE\_3DY\_UP, LI\_PBMC\_MENACTRA\_AGE\_18\_45YO\_ANTI\_DT\_ANTIBODY\_CORRELATION\_PROFILE\_3DY\_UP  
GAUCHER\_PBMC\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_10DY\_UP, GAUCHER\_PBMC\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_10DY\_UP  
FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_TO\_48HR\_EARLY\_UP, FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_TO\_48HR\_EARLY\_UP  
HOWARD\_NEUTROPHIL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_DN, HOWARD\_NEUTROPHIL\_INACT\_MONOV\_INFLUENZA\_A\_INDONESIA\_05\_2005\_H5N1\_AGE\_18\_49YO\_1DY\_DN  
PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGE\_3DY\_UP, PATEL\_SKIN\_OF\_BODY\_ZOSTAVAX\_AGE\_70\_93YO\_VZV\_CHALLENGE\_3DY\_UP  
SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_50\_TO\_60DY\_DN, SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_50\_TO\_60DY\_DN  
QI\_PBMC\_ZOSTAVAX\_AGE\_50\_75YO\_CORRELATED\_WITH\_T\_CELL\_RESPONSES\_1D\_INFORMATIVE\_OF\_LONG\_TERM\_RESPONSES\_NEGATIVE, QI\_PBMC\_ZOSTAVAX\_AGE\_50\_75YO\_CORRELATED\_WITH\_T\_CELL\_RESPONSES\_1D\_INFORMATIVE\_OF\_LONG\_TERM\_RESPONSES  
FRANCO\_BLOOD\_SANOFI\_PASTEUR\_SA\_INACTIVATED\_INFLUENZA\_VACCINE\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_AGE\_18\_40YO\_1DY\_POSITIVE, FRANCO\_BLOOD\_SANOFI\_PASTEUR\_SA\_INACTIVATED\_INFLUENZA\_VACCINE\_CORRELATED\_WITH\_ANTIBODY  
SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_50\_TO\_60DY\_UP, SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_50\_TO\_60DY\_UP  
SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_5\_TO\_7DY\_DN, SCHERER\_PBMC\_APSV\_WETVAX\_AGE\_18\_32YO\_5\_TO\_7DY\_DN  
LI\_PBMC\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_18\_45YO\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_3DY\_POSITIVE, LI\_PBMC\_MENOMUNE\_A\_C\_Y\_W\_135\_AGE\_18\_45YO\_CORRELATED\_WITH\_ANTIBODY\_RESPONSE\_3DY\_POSITIVE  
SOBOLEV\_PBMC\_PANDEMRIX\_AGE\_18\_64YO\_LOW\_VS\_MEDIUM\_HIGH\_ADVERSE\_EVENT\_SUBJECTS\_0DY\_DN, SOBOLEV\_PBMC\_PANDEMRIX\_AGE\_18\_64YO\_LOW\_VS\_MEDIUM\_HIGH\_ADVERSE\_EVENT\_SUBJECTS\_0DY\_DN  
GAUCHER\_PBMC\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_60DY\_UP, GAUCHER\_PBMC\_YF\_VAX\_STAMARIL\_UNKNOWN\_AGE\_60DY\_UP  
MATSUMIYA\_PBMC\_MODIFIED\_VACCINIA\_ANKARA\_VACCINE\_AGE\_18\_55YO\_VACCINATED\_VS\_CONTROL\_TREATED\_IN\_VITRO\_WITH\_MVA85A\_6HR\_UP, MATSUMIYA\_PBMC\_MODIFIED\_VACCINIA\_ANKARA\_VACCINE\_AGE\_18\_55YO\_VACCINATED\_VS\_CONTROL\_TRE  
NAKAYA\_PBMC\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_GENES\_IN\_BTMM40\_AND\_M53\_UP, NAKAYA\_PBMC\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_GENES\_IN\_BTMM40  
FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_UP, FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_UP  
ZAK\_PBMC\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_3DY\_UP, ZAK\_PBMC\_MRKAD5\_HIV\_1\_GAG\_POL\_NEF\_AGE\_20\_50YO\_3DY\_UP  
FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_48HR\_UP, FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_48HR\_UP  
FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_336HR\_UP, FULLER\_PBMC\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_336HR\_UP  
NAKAYA\_PBMC\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_ATIV\_UP, NAKAYA\_PBMC\_FLUAD\_MALE\_AGE\_14\_27YO\_1D\_POSTBOOST\_VS\_0D\_PREIMM\_MF59\_ADJUVANTED\_1DY\_ATIV\_UP